Riskpilot← Back to searchSign inGet full accessNordiskt Endoskopicentrum AB
ABBankruptOrg 5590543053General medical practice activities · NACE 8621Est. 20160 employees
Revenue 2024
SEK 24,6M
+30% vs 2023
EBITDA margin
5.8%
-31% vs 2023
Equity ratio
28.4%
Financial strength
Net profit 2024
SEK 738K
-33% vs 2023
| Revenue | SEK 24,6M | +30% |
| EBITDA | SEK 1,4M | -31% |
| Net profit | SEK 738K | -33% |
| Total assets | SEK 6,1M | -10% |
| Equity | SEK 1,7M | -21% |
| Employees | 0 | — |
Legal name
Nordiskt Endoskopicentrum AB
Org number
5590543053
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
8 mars 2016
Share capital
SEK 60 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva verksamhet inom hälso- och sjukvård, företrädesvis avseende magtarm undersökningar, medicinsk rådgivning, utbildning och undervisning, handel med medicinsk utrustning samt därmed förenlig verksamhet.
Address
Email
info@nordiskt-endoskopicentrum.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 783 | 6 564 | 13 165 | 18 838 | 24 580 |
| Staff expenses | — | — | — | −7 496 | −8 391 |
| EBITDA | 276 | 331 | 1 883 | 2 064 | 1 434 |
| Depreciation & amort. | −49 | −113 | −212 | −222 | −186 |
| EBIT | 227 | 218 | 1 671 | 1 842 | 1 248 |
| Net financials | −1 | −8 | −3 | −1 | 10 |
| Profit before tax | 227 | 166 | 1 711 | 1 374 | 937 |
| Tax | −28 | −38 | −356 | −272 | −199 |
| Net profit | 199 | 128 | 1 355 | 1 102 | 738 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 656 | 2 321 | 3 645 | 6 770 | 6 067 |
| Equity | 262 | 327 | 1 682 | 2 184 | 1 722 |
| Long-term debt | 407 | 0 | 0 | — | — |
| Short-term debt | 987 | 1 950 | 1 962 | 4 120 | 3 558 |
| Total debt | 1 394 | 1 950 | 1 962 | 4 120 | 3 558 |
EBITDA margin
5.8%
This company
15.8%
Market median
-63% vs market
20202024
Equity ratio
28.4%
This company
38.2%
Market median
-26% vs market
20202024
Return on equity
42.9%
This company
18.4%
Market median
+133% vs market
20202024
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20202024
Asset turnover
4.05×
This company
1.12×
Market median
+262% vs market
20202024
Debt / equity
2.52×
This company
0.62×
Market median
-306% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CL | Audit | 2022 |
| Former (1) | ||
CM | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordiskt Endoskopicentrum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Magnus Gustaf Kollberg | Audit | 0 companies |
| Carl Ludvig Gustaf Kollberg | Audit | 0 companies |
| Morteza Shafazand | Board of Directors | 0 companies |
| Anna Erika Eurenius | Chairman | 0 companies |
| Tomasz Radomski | Board of Directors | 0 companies |